Abstract 484P
Background
In the LUX-Lung (LL) 3 and 6 trials, first-line afatinib significantly improved PFS vs chemotherapy in pts with EGFRm+ NSCLC and baseline brain mets (HR, 0.50; P = 0.03).1 In LL7, similar PFS improvement with afatinib vs gefitinib was observed in pts with, and without, brain metastases (HR, 0.76 and 0.74; Pint=0.93).2 Competing risk analysis of LL3/6 demonstrated low risk of de novo CNS progression in pts treated with afatinib (6%).3 Here, we assess afatinib in pts with brain metastases treated in a ‘real-world’ setting.
Methods
Retrospective pooled analysis of three ‘real-world’ studies: a multi-center expanded-access program in Korea (1200.193); an Asian phase IIIB trial (1200.66); a global phase IIIB trial (mainly Europe; 1200.55). All three studies recruited EGFR TKI-naïve pts with EGFRm+ NSCLC who received afatinib 40 mg/day, including pts with asymptomatic brain metastases. Dose reduction was permitted (minimum 20 mg/day). Endpoints included investigator-assessed progression-free survival (PFS), time to symptomatic progression (TTSP) and objective response rate (ORR).
Results
A total of 1108 pts were treated with afatinib. Baseline characteristics were: median age, 61 yrs; female, 58%; ECOG PS of 0/1/2, 26%/70%/4%; uncommon EGFR mutations: 18%; first-line afatinib, 69%. In total, 213 pts had brain metastases. Median PFS and TTSP in these pts were 10.6 months (95% CI 9.1–12.8) and 13.7 months (95% CI 11.0–14.8), respectively. When restricted to pts harboring common EGFR mutations, median PFS and TTSP were 11.7 months (95% CI 10.1–13.8) and 14.4 months (95% CI 12.9–16.4), respectively. ORR was 57% (59% in pts with common EGFR mutations); median duration of response was 11.1 months (95% CI 8.3–12.3).
Conclusions
Consistent with clinical trial data, afatinib is active in pts with EGFRm+ NSCLC and brain metastases treated in a real-world setting in Asian and Caucasian pts. 1. Schuler, M. et al. J Thorac Oncol 2016;11:380–90 2. Park, K. et al. Lancet Oncol 2016;17:577–89 3. Girard, N. Future Oncol. 2018;14:1117–32.
Clinical trial identification
NCT01931306; NCT01953913; NCT01853826.
Editorial acknowledgement
Lynn Pritchard of GeoMed, an Ashfield company, part of UDG Healthcare plc.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
F. de Marinis: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Advisory / Consultancy: Takeda; Research grant / Funding (institution): Boehringer Ingelheim. V. Lee: Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self): Eli Lilly; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Merck Sharp & Dohme. L. Clementi: Full / Part-time employment: Boehringer Ingelheim . W. Tang: Full / Part-time employment: Boehringer Ingelheim . D.C-L. Huang: Full / Part-time employment: Boehringer Ingelheim . A. Cseh: Full / Part-time employment: Boehringer Ingelheim . K. Park: Advisory / Consultancy: AMGEN; Advisory / Consultancy: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: BluePrint; Advisory / Consultancy: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Hanmi; Advisory / Consultancy: KHK; Advisory / Consultancy: Loxo; Advisory / Consultancy: Merch KGaA; Advisory / Consultancy, Research grant / Funding (self): MSD; Advisory / Consultancy: ONO; Advisory / Consultancy: Roche. C. Zhou: Honoraria (self): BI; Honoraria (self): Roche; Honoraria (self): Sanofi; Honoraria (self): Hengrui; Honoraria (self): Qilu; Honoraria (self): MSD. Y-L. Wu: Honoraria (self), Advisory / Consultancy: AZ; Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy: BMS; Full / Part-time employment: Guangdong Provincial People\'s Hospital, China; Honoraria (self): Eli Lilly; Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (self): BI. All other authors have declared no conflicts of interest.
Resources from the same session
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract